Abstract:
Infectious diseases are an important cause of mortality and morbidity, causing approximately 27% of the total disease burden in DALY. A large part of DALY lost due to infectious diseases could be prevented by improving existing vaccination programs for the population. Diseases such as childhood cluster diseases, hepatitis A and B, respiratory infections caused by influenza, pneumococcal and meningococcal infections, and Hemophilus influenzae type B, are for a large part preventable by current vaccines.
The implementation of new vaccine programs or/and strategies is often a costly process with long term consequences. Vaccination programs often concern a large part of the population, and have a large budget impact. Once a vaccination program has started, it is (due to equity reasons) extremely difficult to cease the program. To gain a better understanding of the potential impact on health benefits and costs of a vaccine intervention, health-economic evaluations are frequently used, which estimate the future impact on health gains and costs. Health-economic evaluations are mostly presented as one of the following four types of analysis: cost-minimization, cost-benefit, cost-effectiveness and cost-utility analysis. In this chapter, we provide an overview of the main techniques and challenges associated with health economic evaluations of vaccination programs, such as the choice of the model. Additionally, an overview of health economic evaluations that have been performed on currently implemented vaccination strategies is presented. From our analysis it follows that vaccine programs, and especially those against childhood cluster diseases, and vaccination of elderly against influenza are amongst the world’s most cost-effective interventions.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The force of infection is defined as the per-susceptible rate of infection. The force of infection can be calculated approximately by dividing the incidence by the number of susceptibles
Abbreviations
- BCG:
-
bacillus Calmette-Guérin
- CBA:
- CEA:
-
cost effectiveness analysis
- CMA:
-
cost minimization analysis
- DALY:
-
disability adjusted life year
- DTPP:
-
diphtheria, tetanus, pertussis and poliomyelitis
- Hib:
-
Hemophilus influenzae type b
- HPV:
-
human papilloma virus
- IPV:
-
inactivated poliomyelitis vaccine
- MMR:
-
measles, mumps and rubella
- OPV:
-
oral poliomyelitis vaccine
- QALY:
-
quality adjusted life year
- WTP:
-
willingness to pay
- VZV:
-
varicella zoster virus
References
Akumu A, English M, et al. (2007). Bull World Health Organ. 85(7): 511–518.
Anderson RM, May RM. (1991). Infectious Diseases of Humans; Dynamics and Control. Oxford University Press, New York.
Anonychuk A, Tricco A, et al. (2008). Pharmacoeconomics. 26: 17–32.
Austrian R. (1981). Proc Am Philos Soc. 125(1): 46–51.
Baker CJ. (2007). N Engl J Med. 357: 1757–1759.
Banz K, Wagenpfeil S, et al. (2003). Vaccine. 21: 1256–1267.
Bart K, Foulds J, et al. (1996). Bull World Health Organ. 74: 35–45.
Beutels P. (2001). Health Econ. 10: 751–774.
Beutels P, Bonanni P, et al. (1999). Vaccine. 17(19): 2400–2409.
Beutels P, Edmunds WJ, et al. (2002). Pharmacoeconomics. 20: 1–7.
Beutels P, Gay NJ. (2003). Epidemiol Infect. 130(2): 273–283.
Beutels P, Thiry N, van Damme P. (2007). Vaccine. 25(8): 1355–1367.
Bilcke J, Beutels P, et al. (2007). Cost-Effectiveness of Rotavirus Vaccination of Infants in Belgium. KCE, Brussels.
Bonanni P, Pesavento G, et al. (2003). Vaccine. 21: 685–691.
Bos JM, van Alphen L, et al. (2008). “The use of modelling in the economic evaluation of vaccines. Expert Rev Pharmacoeconomics Outcomes Res. 2(5): 443–455.
Brisson M, Edmunds WJ. (2002). Vaccine. 20: 1113–1125.
Brisson M, Edmunds WJ, et al. (2000a). Vaccine. 18: 2775–2778.
Brisson M, Edmunds WJ, et al. (2000b). Epidemiol Infect. 125: 651–669.
Broughton E. (2007). J Public Health (Oxf). 29(4): 441–448.
Burls A, Jordan R, et al. (2006). Vaccine. 24(19): 4212–4221.
Caro J, Getsios D, et al. (2005). Pediatr Infect Dis J. 24(Suppl): S75–S82.
Caro JJ, Getsios D, et al. (2005). Pediatr Infect Dis J. 24(5 Suppl): S48–S54.
Clemens J, Brenner R, et al. (1996). JAMA 275: 390–397.
Cookson R, Mc Daid D. (2003). Health Policy 63: 133–139.
Dasbach E, Elbasha E, et al. (2006). Epidemiol Rev 28: 88–100.
Edmunds WJ, Brisson M, et al. (2001). Vaccine. 19: 3076–3090.
Edmunds WJ, Brisson M, et al. (2002). Vaccine. 20: 1316–1330.
Edmunds WJ, Medley GF, et al. (1999). Stat Med. 18: 3262–3282.
Ekwueme DU, Strebel PM, et al. (2000). Arch Pediatr Adolesc Med. 154: 797–803.
Evers S, Ament A, et al. (2007). Eur J Clin Microbiol. 26: 531–540.
Frazer I. (2007). Int J Infect Dis. 11: S10–S16.
Gay NJ, Pelletier L, et al. (1998). Vaccine. 16(8): 794–801.
Gwatkin DR, Guillot M. (1998). The Burden of Tropical Diseases Among the Poorest and Richest 20% of the Global Population. TDR/ER/RD/96.1, World Health Organization.
Hay J, Daum R, et al. (1987). Pediatrics 80(3): 319–329.
Hinman AR, Irons B, et al. (2002). Bull World Health Organ 80(4): 264–270.
Iskedjian M, Walter JH, et al. (2004). Vaccine. 22: 4215–4227.
Jacobs R, Koff R, et al. (2002). Am J Gastroenterol. 97: 427–434.
Jefferson T, Behrens R, et al. (1994). Vaccine. 12: 1379–1383.
Jit M, Edmunds W. (2007). Vaccine. 25: 3971–3979
Johannesson M, Meltzer D. (1998). Health Econ. 7(1): 1–7.
Kahn MM, Ehreth J. (2003). Vaccine. 21: 702–705.
Martens L, ten Velden G, et al. (1991). Ned Tijdschr Geneeskd. 135(1): 16–20.
Miller E, Marshall R, et al. (1993). Rev Med Microbiol. 4: 222–230.
Miller MA, Redd S, et al. (1998). Vaccine. 16(20): 1917–1922.
Paavonen J, Jenkins D, et al. (2007). Lancet. 369: 2161–2170.
Parkin D, Bray F. (2006). Vaccine. 24: S11–S25.
Pelletier L, Chung P, et al. (1998). Vaccine. 16(9): 989–996.
Platonov A, Griffiths U, et al. (2006). Vaccine. 24(13): 2367–2376.
Plotkin SA Mortimer EA. (1994). Vaccines, 2nd ed. W.B. Saunders Company, New York.
Pokorn M, Kopac S, et al. (2001). Vaccine. 19(25–26): 3600–3605.
Postma M, Jansema P, et al. (2002). Drugs. 62(7): 1013–1024.
Postma MJ, Bos JM, et al. (2003). Eur J Health Econ.
Purdy KW, Hay JW, et al. (2004). Clin Infect Dis. 39: 20–28.
Sellick JA, Jr., Longbine D, et al. (1992). Ann Intern Med. 116(12 Pt 1): 982–984.
Sénécal M, Brisson M, et al. (2006). Quality of Life Lost Associated with Rotavirus Gastroenteritis in Canadian Families: A Prospective Community Based Study. 7th Canadian Immunization Conference, Winnipeg.
Seward JF, Jumaan AO, et al. (2002). JAMA. 287: 2211–2222.
Shiell A, Jorm LR, et al. (1998). Aust N Z J Public Health. 22(1): 126–132.
Sisk J, Whang W, et al. (2003). Ann Intern Med. 138.
Stevenson M, Beard S, et al. (2002). Vaccine. 20: 1778–1786.
Stover BH, Adams G, et al. (1994). Infect Control Hosp Epidemiol. 15(1): 18–21.
Thiry N, Beutels P, et al. (2003). Pharmacoeconomics. 21: 13–18.
Thompson KM, Duintjer Tebbens RJ. (2006). Risk Anal. 26: 1423–1440.
Thompson KM, Duintjer Tebbens RJ. (2007). Lancet. 369: 1363–1371.
Tormans G, Van Doorslaer E, et al. (1998). Eur J Pediatr. 157: 395–401.
Vesikari T, Matson D, et al. (2006). N Engl J Med. 354: 23–33.
Welte R, Trotter CL, et al. (2005). Pharmacoeconomics. 23(9): 855–874.
White CC, Koplan JP, et al. (1985). Am J Public Health. 75: 739–744.
Whitney G, Farley M, et al. (2003). N Engl J Med. 348: 1737–1746.
WHO. (2007). The World Health Report 2007 – A safer future: global public health security in the 21st century.
WHO. (2008). Immunisation fact sheet Nr 288.
Widdowson M, Meltzer M, et al. (2007). Pediatrics 119: 684–697.
Wood S, Nguyen V, et al. (2000). Pharmacoeconomics. 18(2): 173–183.
Zwanziger J, Szilagyi PG, et al. (2001). Health Serv Res. 36(5): 885–909.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Bos, J., Postma, M. (2010). Economics and Vaccines. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_77
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_77
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine